Blog
RSS FeedPosted by Michael Wonder on 08 Feb 2021
FDA grants breakthrough device designation for Roche's Elecsys growth differentiation factor-15 assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients
8 February 2021 - FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to ...
Posted by Michael Wonder on 08 Feb 2021
Puzzle Medical Devices receives U.S. FDA breakthrough device designation for its revolutionary minimally invasive transcatheter heart pump
8 February 2021 - Puzzle Medical Devices announced today that the U.S. FDA has granted the company a breakthrough revice designation ...
Posted by Michael Wonder on 07 Feb 2021
Novavax announces start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorisation
4 February 2021 - Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada. ...
Posted by Michael Wonder on 06 Feb 2021
FDA blasts Keytruda data for new breast cancer indication as ‘questionable, immature, and unreliable’
5 February 2021 - Merck may have readily turned its Keytruda cancer drug into a medical and financial juggernaut, but ...
Posted by Michael Wonder on 06 Feb 2021
FDA authorises marketing of novel device to reduce snoring and mild obstructive sleep apnea in patients 18 years and older
5 February 2021 - Today, the U.S. FDA authorised marketing of a new prescription only device intended to reduce snoring and ...
Posted by Michael Wonder on 06 Feb 2021
FDA announces Advisory Committee meeting to discuss Janssen Biotech’s COVID-19 vaccine candidate
4 February 2021 - The U.S. FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on ...
Posted by Michael Wonder on 06 Feb 2021
Johnson & Johnson announces submission of application to the U.S. FDA for Emergency Use Authorisation of its investigational single shot Janssen COVID-19 vaccine candidate
4 February 2021 - Johnson & Johnson intends to distribute vaccine to the U.S. government immediately following authorisation, and expects to ...
Posted by Michael Wonder on 06 Feb 2021
FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma
5 February 2021 - Today, the FDA approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics) for the treatment of adult patients with ...
Posted by Michael Wonder on 06 Feb 2021
FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma
5 February 2021 - Today, the Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase ...
Posted by Michael Wonder on 05 Feb 2021
FDA grants Actinogen rare paediatric disease designation in Fragile X syndrome
5 February 2021 - Actinogen is pleased to announce that the United States FDA has granted Actinogen’s drug Xanamem rare paediatric ...
Posted by Michael Wonder on 04 Feb 2021
Theratechnologies’ lead peptide drug conjugate TH1902 receives FDA fast track designation for the treatment of sortilin-expressing cancers
4 February 2021 - Theratechnologies is pleased to announce that the United States FDA has granted fast track designation to TH1902 ...
Posted by Michael Wonder on 03 Feb 2021
FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer
3 February 2021 - Today the FDA granted accelerated approval to tepotinib (Tepmetko, EMD Serono) for adult patients with metastatic ...
Posted by Michael Wonder on 03 Feb 2021
Asana BioSciences’ gusacitinib granted FDA fast track designation for moderate to severe chronic hand eczema
4 February 2021 - Asana BioSciences announced today that the U.S. FDA has granted fast track designation to Asana’s gusacitinib (ASN002), ...
Posted by Michael Wonder on 03 Feb 2021
BioCryst announces FDA approval of supplemental new drug application for Rapivab expanding patient population to include children six months and older
3 February 2021 - BioCryst Pharmaceuticals today announced that the U.S. FDA has approved a supplemental new drug application for ...
Posted by Michael Wonder on 03 Feb 2021
Durect Corporation announces U.S. FDA approval of Posimir for post-surgical pain reduction for up to 72 hours following arthroscopic subacromial decompression
2 February 2021 - POSIMIR is the only approved sustained release bupivacaine product indicated for up to 72 hours of post-surgical ...